With its own COVID-19 vaccine trial on pause, Sanofi will produce 12 million doses of Johnson & Johnson’s candidate

While its own COVID-19 vaccine candidate faces trial delays, French drug maker Sanofi will use its vaccine manufacturing plant in Marcy L'Etoike, France, to formulate and fill vials with Johnson & Johnson's single-dose shot. The goal, Sanofi said, is to produce about 12 million doses in its facility.

The companies are considered rivals, but Sanofi CEO Paul Hudson said the company is "stepping forward to show solidarity" amid the coronavirus pandemic, even as it remains focused on eventually moving forward with its own trials.

Sanofi previously agreed to help bottle and package 125 million doses of the COVID-19 vaccine developed by Pfizer and BioNTech. Read more at The Associated Press.

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up